Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CCT301-38 and CCT301-59 in Recurrent or Refractory Stage IV Renal Cell Carcinoma
NCT03393936Phase 2Terminated
- Sponsor
- Shanghai PerHum Therapeutics
- Start
- Mar 2018
- Primary completion
- Jun 2022
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 1
01
Overview
Phase 2, open-label trial of CCT301-38 and CCT301-59 in renal cell carcinoma (RCC), sponsored by Shanghai PerHum Therapeutics. Primary endpoints: Dose-Limiting Toxicities at 28 days and Objective Response Rate at 9 months. Started Mar 2018; status: terminated.
02
Drugs
CCT301-38CCT301-59
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT03393936.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03393936.